Back to Search Start Over

Neurocognitive functioning after Gamma Knife and LINAC stereotactic radiosurgery in patients with brain metastases.

Authors :
Albers EAC
de Ruiter MB
van de Poll-Franse LV
Merckel LG
Compter A
Schagen SB
Source :
Journal of neuro-oncology [J Neurooncol] 2022 Dec; Vol. 160 (3), pp. 649-658. Date of Electronic Publication: 2022 Dec 01.
Publication Year :
2022

Abstract

Purpose: Brain metastases (BM) themselves and treatment with stereotactic radiosurgery (SRS) can influence neurocognitive functioning. This prospective study aimed to assess neurocognitive decline in patients with BM after SRS.<br />Methods: A neuropsychological test battery was assessed yielding ten test outcomes. Neurocognitive decline at 3 and 6 months post SRS was compared to measurement prior to Gamma Knife (GK) or linear accelerator (LINAC) SRS. Reliable change indices with correction for practice effects were calculated to determine the percentage of neurocognitive decline (defined as decline on ≥ 2 test outcomes). Risk factors of neurocognitive decline were analyzed with binary logistic regression.<br />Results: Of 194 patients pre-SRS, 40 GK and 29 LINAC patients had data accessible at 6 months. Compared to baseline, 38% of GK patients declined at 3 months, and 23% declined at 6 months. GK patients declined on attention, executive functioning, verbal memory, and fine motor skill. Of LINAC patients, 10% declined at 3 months, and 24% at 6 months. LINAC patients declined on executive functioning, verbal memory, and fine motor skills. Risk factors of neurocognitive decline at 3 months were high age, low education level and type of SRS (GK or LINAC). At 6 months, high age was a risk factor. Karnofsky Performance Scale, BM volume, number of BM, tumor progression and neurocognitive impairment pre-SRS were no risk factors.<br />Conclusion: Neurocognitive decline occurs in a considerable proportion of patients with BM treated with GK or LINAC SRS. Overall, high age appears to be a risk factor for neurocognitive decline after SRS.<br /> (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Details

Language :
English
ISSN :
1573-7373
Volume :
160
Issue :
3
Database :
MEDLINE
Journal :
Journal of neuro-oncology
Publication Type :
Academic Journal
Accession number :
36454373
Full Text :
https://doi.org/10.1007/s11060-022-04185-3